Table 2 The demographic data of 17 Taiwanese patients with MPS born between 2016 and 2019
From: Survival and diagnostic age of 175 Taiwanese patients with mucopolysaccharidoses (1985–2019)
No | Year of birth | Year of diagnosis | Age of diagnosis (years) | MPS type | Referring origin | Management |
|---|---|---|---|---|---|---|
1 | 2019 | 2019 | 0.2 | I | NBS | ERT |
2 | 2019 | 2019 | 0.2 | II | NBS | ERT + HSCT |
3 | 2018 | 2019 | 0.1 | II | NBS | ERT + HSCT |
4 | 2018 | 2018 | 0.1 | IVA | NBS | ERT |
5 | 2018 | 2019 | 0.1 | IIIB | NBS | Regular follow-up |
6 | 2018 | 2019 | 1.4 | IVA | NBS | ERT |
7 | 2017 | 2017 | 0.1 | II | NBS | ERT + HSCT |
8 | 2017 | 2018 | 0.2 | II | NBS | ERT |
9 | 2017 | 2017 | 0.4 | I | NBS | Regular follow-up |
10 | 2017 | 2018 | 0.5 | II | NBS | Regular follow-up |
11 | 2016 | 2016 | 0.1 | I | NBS | Regular follow-up |
12 | 2016 | 2016 | 0.1 | I | NBS | Regular follow-up |
13 | 2016 | 2016 | 0.1 | II | NBS | Regular follow-up |
14 | 2016 | 2016 | 0.2 | I | NBS | Regular follow-up |
15 | 2016 | 2017 | 0.4 | I | NBS | ERT |
16 | 2016 | 2018 | 1.6 | I | NBS | ERT |
17 | 2016 | 2017 | 1.6 | IVA | Clinical indication | ERT |